UNSPSC 51433003: Rilmenidine dihydrogen phosphate

This classification denotes an antihypertensive agent with the molecular formula C10H16N2O.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59QD64Q32M, chemically known as 4,5-dihydro-n-(dicyclopropylmethyl)-2-oxazolamine phosphate (1:1) but more generally known as rilmenidine dihydrogen phosphate, which bears US NIH Compound Identifier 198614. European Medicines Agency schedules Rilmenidine phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21586.

Most nations, for tariff and trade purposes, schedule rilmenidine dihydrogen phosphate under HS 29349990. SMILES: C1CC1C(C2CC2)NC3=NCCO3.OP(=O)(O)O.

UNSPSC 51433003 Rilmenidine dihydrogen phosphate is a Commodity code that encompasses branded and generic pharmaceutical active ingredients and finished-dose medications supplied to state and local health systems, emergency services, and public health programs. State and local governments procure medications under this code through direct purchase from manufacturers and authorized wholesalers to support emergency medical services, institutional pharmacy operations, and public health initiatives. The solicitations show mixed demand: some jurisdictions issue sealed competitive bids for specific finished medications with immediate operational needs (such as emergency drugs for paramedics), while others use cooperative purchasing vehicles and RFPs to establish standing supplier relationships for broad pharmaceutical catalogs across multiple state and local facilities.

Recent activity centers on Florida and Minnesota with a secondary engagement in Texas. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, seeking four specific Advanced Life Support medications (Labetalol, Epinephrine, Adenosine, Diltiazem) for Tampa Fire Rescue, with bids due April 8, 2026 and an estimated contract value of $40,000 under a Small Local Business Enterprise sheltered-market designation with a 5 percent SLBE bid discount capped at $10,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to supply through three authorized wholesalers with awards effective July 1, 2026 and a two-year initial term. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, as a preliminary market-intelligence solicitation regarding direct-to-manufacturer prescription programs without specified award values or formal evaluation criteria at that stage. The code shows modest but geographically dispersed state and local procurement activity driven by standing operational requirements and cooperative purchasing frameworks.